Please complete our survey to better understand how prescription medicines and nutraceuticals are currently used by those living with DMD
Please complete our survey to better understand how prescription medicines and nutraceuticals are currently used by those living with Duchenne Muscular Dystrophy in the UK.
Duchenne UK is testing a number of what are called repurposed medicines to see if they are effective in DMD. Repurposed medicines are medicines that are already approved for use in one condition, which may show promise in other diseases. Please read about one example, the Tamoxifen trial, Duchenne UK is co-funding.
We would like to invite parents/caregivers and patients with DMD to complete our survey to help us better understand how medicines (prescription and non-prescription) and nutraceuticals are currently being used by those living with Duchenne muscular dystrophy (DMD).
We require some feedback from the Duchenne Community that will help us understand: -
- What prescription medications are taken by those living with DMD.
- To what extent patients are sourcing their own prescription medications (un-prescribed or off-label).
- What nutraceuticals are taken by those living with DMD.
The results of the survey will help Duchenne UK make informed decisions about the development of repurposed drugs as potential treatments for DMD and will facilitate clinical trial planning.
They survey is completely anonymous and will not ask you for any personal details.
The survey can be filled in via your mobile, PC or Laptop and will take no more than 20 minutes to complete.
You can complete the survey by clicking the link below:
If you are a caregiver for more than one child/adult living with DMD please complete one for each child/adult as experiences for each may be different for each.
The survey will close at midnight on Tuesday 2nd January 2019.
Duchenne UK would like to thank you in advance for providing such valuable information and helping us move a step forward in increasing our knowledge in such an important area within Duchenne research.
For more information please contact [email protected]
Published on 12 December 2018Share this articleCategories Uncategorised